Cytosystems Ltd is a Scottish-based company set up in 2006 to develop advanced, laboratory-based diagnostic tests for cancer which are aimed at replacing invasive, distressing and expensive endoscopic test procedures like cystoscopy.

Cytosystems has secured exclusive worldwide licence rights from Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, for the deployment of MCM protein antibody diagnostics in bladder and prostate cancer.  Having completed two major clinical trials in UK teaching hospitals, Cytosystems is continuing to analyse the study outcomes to validate the use of MCM technologies in these fields. Projected publication of the results for the bladder cancer study is Q4, 2011.

Cytosystems has developed a unique urine-based screening and diagnostic solution for the detection of cancer of the bladder and the prostate comprising:

• Urine collection protocols
• Patented cell harvesting device*
• MCM protein antibody
• Patented staining technology
• Thin slide preparation
• Digital cell recognition software

Independent research has confirmed that successfully introducing a nurse-managed diagnostic solution of this type into the clinic could enable earlier, more accurate diagnosis, improve patient care, enhance outcomes and greatly reduce associated healthcare costs by as much as a projected >50%.

The core MCM technology was developed over a twelve-year period by Cancer Research UK at Cambridge University.

*Protected by international patent no. WO 2009/087375 A1

Click here for more about Cytosystems’ platform technology.